TMX-049, Phase 2 Study

A Exploratory Phase 2,Placebo-controlled,Randomized,Double-blind,Multicenter,Parallel-group Study to Evaluate Efficacy and Safety of TMX-049 in Hyperuricemic Patients with or without Gout

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223522

Enrollment

120

Registered

2017-05-11

Start date

2017-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia with or without gout

Interventions

investigational material(s) Generic name etc : TMX-049 INN of investigational material : Therapeutic category code : 394 Agents for treatment of gout Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hyperuricemic patients with or without gout

Exclusion criteria

Exclusion criteria: Subjects with gouty arthritis Subjects with secondary hyperuricemia etc.

Design outcomes

Primary

Measure	Time frame
Percent change of serum urate from baseline to Week 16	—

Secondary

Measure	Time frame
Percentage of subjects with serum urate =< 6.0 mg/dL at Week 16 Percent change of serum urate in each examination	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026